Administering a combination of low‐dose tissue‐type plasminogen activator (tPA) plus recombinant human Annexin A2 (rA2) four hours post‐ischemic stroke yields superior enhancement in neurological function recovery [17]. This evidence concerns the gene ANXA2 and ischemic stroke.